HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Are Rx-To-OTC Switches Worth The Trouble? Yes They Are, IQVIA Data Shows

Executive Summary

The holy grail of consumer health innovation, Rx-to-OTC switches, are costly and hard to pull off. So, are they worth the effort? An analysis by IQVIA of desloratadine, which was switched in Germany 2020 by Novartis subsidiary, Hexal, shows that they are, with sales of OTC desloratadine products growing 112% between 2019 and 2020. 

You may also be interested in...



Top 10 UK OTC Marketing Stories 2021: Switches And Digital Prove Popular

Despite the restrictions on daily life due to the pandemic, 2021 was still a great year for consumer health product marketing, with brands and their agencies devising innovative ways to reach UK consumers. Here we look at HBW Insight's top-10 most read UK marketing stories of 2021, revealing those launches, campaigns and trends which grabbed the attention of readers last year.

UK Weighing Rx-to-OTC Switch Of Menopause Treatment

Novo Nordisk is seeking to switch from Rx-to-OTC status Gina (estradiol hemihydrate), which, if approved, would be the first form of local hormone replacement therapy available without a prescription in the UK.

No OTC Sildenafil In Germany After Committee Rejects All Rx-To-OTC Switches

The German Expert Committee for Prescription has rejected the Rx-to-OTC reclassifications of sildenafil (50mg) for oral use and xylometazoline and ipratropium bromide for intranasal use. 

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel